PureTech Health is a biotherapeutics company engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. Co.'s wholly owned pipeline includes therapeutic candidates, such as LYT-100, a clinical therapeutic candidate that it is pursuing for the treatment of a range of conditions involving inflammation and fibrosis and disorders of lymphatic flow; and LYT-200, a clinical immuno-oncology fully human monoclonal antibody candidate targeting a foundational immunosuppressive protein. The PRTC stock yearly return is shown above.
The yearly return on the PRTC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRTC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|